CureVac BV (NASDAQ:CVAC) shares are trading lower by 3.6% at $56 after the CDC said preliminary findings suggest the observed reports of heart inflammation after mRNA COVID-19 vaccines are greater than expected.
CureVac a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
CureVac's product portfolio also includes clinical and pre-clinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy.
Among CureVac's clinical programs are CV8102, which it is evaluating in Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it's investigating in Phase 1 clinical trial for potential vaccination against rabies.